Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy

Table 2

The presence of comorbidities in the study population.

Comorbidities, (%)	Total ()	ICU patients
		Live ()	Dead ()
Hypertension	109 (69.4)	40 (62.5)	69 (74.2)	0.158
Diabetes	52 (33.1)	26 (40.6)	26 (28.0)	0.121
Obesity	14 (8.9)	6 (9.5)	8 (8.5)	1.000
HOBP	8 (5.1)	1 (1.6)	7 (7.5)	0.095
Asthma	6 (3.8)	2 (3.1)	4 (4.3)	0.706
Coronary disease	28 (17.8)	10 (15.6)	18 (19.4)	0.672
Cardiomyopathy	14 (8.9)	6 (9.4)	8 (8.6)	1.000
Number of comorbidities
None	37 (23.7%)	18 (28.6%)	19 (20.4%)	0.457
1	48 (30.8%)	17 (27.0%)	31 (33.3%)
≥2	71 (45.5%)	28 (44.4%)	43 (46.2%)
Total number of patients with comorbidities	120 (76.4%)	46 (71.9%)	74 (79.6%)	0.339